Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa

Boris K. Tchounga1, Charlotte Charpentier2, Patrick A. Coffie3, François Dabis4ab, Diane Descamps2, Serge P. Eholie3, Didier K. Ekouevi4c

1 Programme PACCI, Site de recherche ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire, 2 Université de Paris, INSERM UMR 1137 IAME, Paris, France, 3 Département de Dermatologie et Maladies Infectieuses, Université Félix Houphouët-Boigny, UFR des Sciences Médicales, Abidjan, Côte d’Ivoire, 4 Centre Inserm 1219 & Institut de Santé Publique d’épidémiologie et de développement, Université de Bordeaux, Bordeaux, France

¤a Current address: Elizabeth Glazer Pediatric AIDS Foundation Yaounde Office, Yaounde, Cameroon
¤b Current address: Agence Nationale de recherche sur le SIDA et les Hépatites, Paris, France
¤c Current address: Département de santé Publique, Université de Lomé, Faculté des Sciences de la santé, Lomé, Togo
*boris.tchounga@yahoo.fr

Abstract

Introduction
The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses.

Methods
A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one drug resistance mutation was followed from January 2012 to August 2017 in Côte d’Ivoire. Follow-up data included death, lost to follow-up (LTFU), immuno-virological responses. The Kaplan-Meier curve was used to estimate survival rates.

Results
A total of 31 HIV-2 patients with virologic failure and with at least one drug resistance mutation were included. Two-third of them were men, 28(90.3%) were on PI-based ART-regimen at enrolment and the median age was 50 years (IQR = 46–54). The median baseline CD4 count and viral load were 456 cells/mm3 and 3.7 log10 c/mL respectively, and the participants have been followed-up in median 57 months (IQR = 24–60). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an integrase inhibitor-based regimen respectively. A
total of 10(32.3%) patients died and 4(12.9%) were LTFU. The 36 and 60-months survival rates were 68.5% and 64.9%, respectively. Among the 17 patients remaining in care, six (35.3%) had an undetectable viral load (<50 c/mL) and for the 11 others, the viral load ranged from 2.8 to 5.6 log_{10} c/mL. Twelve patients were receiving lopinavir at the time of first genotype, five(42%) had a genotypic susceptibility score (GSS) \leq 1 and 4(33%) a GSS >2.

**Conclusions**

The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant viruses is below 70%, lower than in HIV-1. There is urgent need to improve access to second-line ART for patients living with HIV-2 in West Africa.

**Introduction**

HIV-2 is responsible for a localized AIDS epidemic that mainly affects the West African region [1–3]. The therapeutic strategy for people living with HIV-2 remain challenging, due to the intrinsic resistance of this virus to non-nucleoside reverse transcriptase inhibitors (NNRTI) and fusion inhibitors, as well as the suboptimal response to some protease inhibitors (PI) [4–6].

In absence of randomized controlled trial, there is no consensus on the therapeutic care of people living with HIV-2 [7,8]. The previous national ART guidelines of West African countries, online with WHO 2010 guidelines, recommended the initiation of a boosting lopinavir/r-based regimen as the preferred option or a three-NRTI based regimen as alternative [9]. The current British, French and USA antiretroviral (ART)-guidelines recommend initiating two NRTI associated with one boosted PI or with one integrase strand-transfer inhibitor (INSTI), and excluded the use of three NRTI as first-line regimen in patients living with HIV-2 [10–12]. More recently, the 2019 WHO guidelines recommended Dolutegravir (DTG) in combination with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone as the preferred first-line regimen for people initiating ART, thus without any difference between those living with HIV-1 and HIV-2 [13]. However, the implementation of this recommendation in low- and middle-income countries, especially those with double circulation of HIV-1 and HIV-2 is ongoing slowly and DTG-based regimen were mainly prescribed to third-line patients in referral centers [14].

In case of virologic failure, HIV-2 patients were enrolled for three months in an enhanced adherence counselling program. If at the end of this period the viral load remained unsuppressed, the patient was eligible to switch treatment. In 2016, West African and European guidelines on the management of treatment failure recommended for HIV-2 patients initially receiving three NRTIs or a LP/r-based regimen as first line, to switch to darunavir (DRV) or raltegravir (RAL) / Dolutegravir (DTG) in combination with NRTI backbone [14]. With the recent recommendation of DTG as preferred first-line regardless of HIV type, the preferred second line recommended by WHO and currently endorsed by West African countries is now LP/r based regimen for HIV-2 patients [13].

Thus management of virologic failure in HIV-2 patients remain challenging despite the guidelines revision, due to the limited options (NRTI, boosted PI) available, while an increasing number of studies reported virologic failure and resistance-associated mutations to NRTIs, PIs and RAL [15–21]. These multiple resistances jeopardize the efficacy of second line HIV-2 treatment, with multidrug resistance needing boosted darunavir plus raltegravir based.

**Funding:** The main study was conducted under the IeDEA West Africa collaboration grants funded by the National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); Grant number: 5U01AI069919 awarded to Pr François Dabis. The specific analyses and results reported in this publication were conducted under the EDCTP2 Training and Mobility Action awarded to Dr Boris Kevin Tchounga as Career Development Fellowship grant. Grant number: TMA 2016 CDF 1597 EDIIIMark-2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have no competing interest to declare.

**Abbreviations:** ART, Antiretroviral therapy; GSS, Genotypic susceptibility score; HIV-2, Human immune deficiency virus type 2; IeDEA, International epidemiologic database to evaluate AIDS; LTFU, Lost to follow up; NNRTI, Non-nucleoside reverse transcriptase inhibitors; NRTI, Nucleoside reverse transcriptase inhibitors; PI, Protease inhibitors.
regimen in resource-limited settings where HIV-2 viral load and genotypic resistance tests are neither routinely available nor affordable.

There is few data reporting experience of therapeutic care and describing long-term outcome of HIV-2-infected individuals experiencing virologic failure in resource-limited settings. Such data will be useful to orient clinicians and decision makers in the management of treatment switches in HIV-2 patients with treatment failure. This survey aimed to describe the sequence of ART regimens use, and the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses in Côte d’Ivoire.

Materials and methods
Study design, population and settings
A clinic-based cohort study was initiated in January 2012 within the International epidemiological Database to evaluate AIDS (IeDEA) in West Africa [22]. The eligibility criteria for this cohort were assessed during a cross-sectional survey conducted to describe virologic failure and drug resistance mutations among HIV-2-infected individuals receiving ART and followed up in six HIV clinics in Abidjan, Côte d’Ivoire [15]. Based on the results of this cross-sectional survey presented elsewhere [15], adults living with HIV-2, experiencing virologic failure, and harboring at least one drug resistance mutation, were included and followed up from 2012 to 2017.

Ethics consideration
The protocol of the IeDEA west Africa collaboration cohort was reviewed and approved in Côte d’Ivoire by the National Ethic Committee for life Science and Health (CNESVS: IORG00075). Prior to the initial enrolment in the cohort, each participant was given comprehensive information on the study protocol and procedures, and had to provide a written consent before being included.

HIV-2 standard of care in Côte d’Ivoire
According to the national guidelines of Côte d’Ivoire at the time of study in 2012, ART was initiated in people living with HIV symptomatic stage 3–4 or asymptomatic with CD4 <350 cells/mm³. In case of HIV-2 or HIV1&2, the preferred first line option was 2 NRTI plus boosted Lopinavir. Three-NRTI-based regimen was considered as alternative option (if CD4 cell counts > 200 cells/mL or Lopinavir contraindication/intolerance) [14]. In case of virologic failure, HIV-2 patients should receive the most appropriate ART regimen available, with the guidance of the national referral center for adults living with HIV (Unit of Infectious and Tropical Diseases Treichville University teaching hospital) [14].

Study procedures
The follow-up consisted in the administration of a standardized questionnaire allowing collection of clinical (AIDS events and Non-AIDS severe morbidity), biological (CD4 count, viral load) and therapeutic (switches second line, salvage ART regimen) data, during routine follow-up visits.

Biological procedures
A comprehensive description of the biological procedure has been published [15]. Briefly, virologic failure was defined as plasma HIV-2 RNA above 50 copies/mL using a real-time PCR assay [23]. Genotypic resistance tests (protease and reverse transcriptase sequencing) were
performed using an in-house method [15]. The interpretation was based on the HIV French resistance algorithm update of September 2017, available at http://www.hivfrenchresistance.org/index.html. A genotypic susceptibility score (GSS) was generated for each patient based on the results of genotypic analyses. In 2017, a blood sample was collected from each participant presenting at the HIV clinic, for a routine follow-up visit or returning to care after a successful tracking process. This blood samples allowed performing a viral load and an additional CD4 count.

**Outcomes and variables**

The main outcomes considered were being alive, dead or LTFU. Considering LTFU like a proxy of death, a variable combining death and LTFU was defined.

Death was defined as being reported dead in the medical records of the HIV clinic or being declared dead by a close relative or a family member. A participant was considered alive if he presented for follow-up visit during the year 2017 or if he was successfully contacted during the active tracking process. The participants who did not showed up at HIV clinic for more than three months, were not known as alive, transferred out or deceased, and were not successfully tracked (phone calls and home visits when allowed in the initial consent form) were considered LTFU.

**Statistical analyses**

Data analysis was conducted using STATA® version 14.0, Stata Corp, College Station, Texas USA. Kaplan Meier curve was used to estimate survival rate and Logrank test was used to compare survival between the two groups.

**Results**

**Baseline characteristics**

Among the 31 participants included in the study, 28 (90.3%) were receiving a PI-based regimen, 2 (6.5%) a three-NRTI-based regimen and 1 (3.2%) a raltegravir-based regimen. The median age at enrolment was 50 years (IQR = 46–54 years) and 20 patients were men (64.5%). At enrolment, the median baseline CD4 count and viral load were 456 cells/mm$^3$ (IQR = 256–751) and 3,700 c/mL (IQR = 663–7797), respectively. The initial genotypic analyses retrieved PI resistance mutations (at least one) in 26 (83.9%) participants and NRTI resistance mutations in 21 (67.7%) participants. The GSS was $<2$ for 14 (45.2%) patients and $>2$ for 10 (32.3%) others (Table 1).

**Follow up characteristics**

The cumulative follow-up duration was 1327 person-months with a median duration of 52 months (IQR = 24–59). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an INSTI-based regimen respectively. At the censured date, 17 (55.0%) patients remained in care, while 10 (32.3%) were dead and 4 (12.9%) were LTFU. The last median CD4 count were 150 cells/mm$^3$ (IQR = 117–218) and 143 cells/mm$^3$ (IQR = 39–340) among patients dead and LTFU, respectively. Among those still in care during follow up, the 12, 36 and 60-months survival rates were 86.8%, 68.8% and 64.9% respectively (Fig 1). Neither gender (HR = 1.57, p = 0.484) nor age $>$50 years (HR = 0.59, p = 0.421) were associated with mortality.

Among the 17 patients remaining in care, six (35.3%) had an undetectable viral load ($<50$ c/mL) and for the 11 others, the median viral load was 4,334 [859–87,523] c/mL, ranging from
### Table 1. Follow-up characteristics of antiretroviral-experienced HIV-2-infected patients with identified resistance mutations from 2012 to 2017.

| Follow-up characteristics | Alive | Death/LTFU | Total | p-values |
|---------------------------|-------|------------|-------|----------|
| n = 17 (55%)              | n = 14 (45%) | n = 31     |       |          |
| Follow-up duration, months Median [IQR] | 60 [58–61] | 19 [12–35] | 57 [24–60] | 0.001 |
| 0.001                      |       |            |       |          |
| Baseline CD4 count cells/mm³ |       |            |       |          |
| Median [IQR]               | 445 [266–675] | 504 [256–855] | 456 [256–751] | 0.489 |
| <350                      | 6 (35.3) | 5 (35.7) | 11 (35.5) |          |
| 350–500                   | 4 (23.5) | 1 (7.2) | 5 (16.1) |          |
| ≥500                      | 7 (42.2) | 7 (50.0) | 14 (45.2) |          |
| Missing                   | 0 (0.0) | 1 (7.1) | 1 (3.2) |          |
| Last CD4 count cells/mm³  |       |            |       |          |
| Median [IQR]              | 281 [193–321] | 150 [113–278] | 230 [120–321] | 0.202 |
| <350                      | 13 (76.4) | 11 (78.7) | 24 (77.4) |          |
| 350–500                   | 2 (11.8) | 1 (7.1) | 3 (9.7) |          |
| ≥500                      | 2 (11.8) | 1 (7.1) | 3 (9.7) |          |
| Missing                   | 0 (0.0) | 1 (7.1) | 1 (3.2) |          |
| Viral load at inclusion c/mL |       |            |       |          |
| Median [IQR]              | 730 [372–4103] | 5992 [3700–16716] | 3700 [663–7797] | 0.007 |
| Viral load at closing date c/mL |       |            |       |          |
| Median [IQR]              | 859 [0–9082] | NA | 859 [0–9082] |          |
| ARV regimen at enrollment |       |            |       |          |
| PI-based                  | 17 (100.0) | 11 (78.6) | 28 (90.3) | 0.568 |
| 3 NRTI-based              | 0 (0.0) | 2 (14.3) | 2 (6.5) |          |
| Raltegravir-based         | 0 (0.0) | 1 (7.1) | 1 (3.2) |          |
| ARV drug switch (at least one) | 12 (70.6) | 9 (64.3) | 21 (67.7) | 0.270 |
| To darunavir*             | 0 (0.0) | 2 (14.3) | 2 (6.5) |          |
| To raltegravir*           | 2 (11.8) | 1 (7.1) | 3 (9.7) |          |
| Genotypic susceptibility score |     |            |       | 0.933 |
| <2                       | 8 (47.1) | 6 (41.9) | 14 (45.2) |          |
| ≥2                       | 5 (29.4) | 5 (35.7) | 10 (32.3) |          |
| Not available            | 4 (23.5) | 3 (21.4) | 7 (22.5) |          |

IQR = interquartile range, LTFU = lost to follow-up, PI = protease inhibitor, NRTI = nucleoside reverse transcriptase inhibitor

* = non-cumulative; NA = not available; ARV = antiretroviral.

https://doi.org/10.1371/journal.pone.0236642.t001

### Fig 1.

![Survival probability vs. follow-up duration in Months](https://doi.org/10.1371/journal.pone.0236642.g001)
584 to 372,346 c/mL (Table 2). Twelve of these patients were receiving lopinavir at time of first genotyping analysis, eight (47.1%) had a GSS <2 and five (29.4%) a GSS >2. Their last median CD4 count was 281 cells/mm$^3$ (IQR = 209–351), not significantly different to those who died or were LTFU ($p = 0.20$). None of participants CD4 increased after switch or after the first virologic failure.

Among the 10 patients declared dead, 6 (60.0%) had CD4 count <200 cells/mm$^3$, 7 (70.0%) had a boosted PI in their last known ART regimen, five (50.0%) had a GSS <2 and 7 (70.0%) changed at least one drug in their ARV regimen at least once after the diagnosis of drug resistance mutation. Regarding treatment, 5 of them switched to an unappropriated and non-effective ART regimen according to the genotypic resistance test. Three of them were maintained on boosted-lopinavir as a compassionate treatment until they died. Two of them received a

### Table 2. Five-years ART-response among HIV-2 infected patients surviving after experiencing treatment failure with identified drug resistance mutations in Côte d’Ivoire, West Africa.

| ID     | Age (years) | Sex | ART regimen at treatment failure | CD4 (cells/mm$^3$) | VL (c/mL) | NRTI Mutations | PI Mutations | GSS | Last ART regimen | CD4 (cells/mm$^3$) | VL (c/mL) |
|--------|-------------|-----|----------------------------------|--------------------|-----------|----------------|--------------|-----|------------------|--------------------|-----------|
| PAT-S01 | 51          | M   | AZT/3TC/LPV/r                    | 106                | 340       | M184V          | V47A, V62A   | 1   | ABC/3TC/LPV/r    | 281                | 859       |
| PAT-S02 | 53          | M   | ABC/3TC/LPV/r                    | 919                | 713       | M184V          | I54M         | 2   | TDF/3TC/LPV/r    | 209                | 4,334     |
| PAT-S03 | 56          | M   | AZT/3TC/LPV/r                    | 675                | 3085      | M184V, S215Y   | V47A, I82M, L90M | 0   | AZT/3TC/LPV/r    | 351                | 372,346   |
| PAT-S04 | 30          | F   | AZT/3TC/LPV/r                    | 119                | 663       | NA             | V47A         | NA  | AZT/3TC/LPV/r    | 291                | 87,523    |
| PAT-S05 | 58          | M   | AZT/3TC/LPV/r                    | 545                | 149       | NA             | Wild-Type    | NA  | TDF/3TC/LPV/r    | 362                | -         |
| PAT-S06 | 60          | F   | ABC/ddI/LPV/r                    | 791                | 4103      | M184V          | NA           | NA  | TDF/3TC/LPV/r    | 79                 | 13,457     |
| PAT-S07 | 33          | M   | SQV/LPV/r                        | 141                | 33287     | Q151M          | I50V, I54M, L90M | 0   | TDF/3TC/DRV/r/ral | 214                | -         |
| PAT-S08 | 50          | M   | ABC/3TC/SQV/r                    | 425                | 8790      | Q151M, K65R, K70R, M184V, K223R | V47A, I50V, I84V, L90M, L99F | 0   | TDF/3TC/DRV/r/ral | 69                 | -         |
| PAT-S09 | 49          | M   | ddI/ABC/LPV/r                    | 751                | 1471      | M184V          | V47A, L99F   | 2   | TDF/3TC/DRV/r    | 256                | 1,535     |
| PAT-S10 | 54          | M   | AZT/3TC/LPV/r                    | 357                | 5156      | Wild-Type      | Wild-Type    | 3   | AZT/3TC/LPV/r    | 103                | 2,337     |
| PAT-S11 | 60          | M   | ABC/ddI/LPV/r                    | 445                | 3016      | Q151M, M184V, S215F | I54M, I84V   | 0   | ABC/3TC/DRV/r    | 193                | 9,082     |
| PAT-S12 | 50          | M   | TDF/FTC/LPV/r                    | 606                | 193       | M184I          | Wild-Type    | 2   | ABC/3TC/LPV/r    | 120                | -         |
| PAT-S13 | 53          | M   | AZT/3TC/LPV/r                    | 157                | 395       | M184V          | V47A         | 1   | AZT/3TC/LPV/r    | 297                | 223,827   |
| PAT-S14 | 43          | F   | TDF/FTC/LPV/r                    | 336                | 91        | M184V          | Wild-Type    | 2   | TDF/3TC/LPV/r    | 774                | -         |
| PAT-S15 | 55          | M   | AZT/3TC/LPV/r                    | 712                | 372       | NA             | V47A         | NA  | AZT/3TC/DRV/r    | 855                | -         |
| PAT-S16 | 53          | M   | AZT/3TC/LPV/r                    | 266                | 730       | M184V, S215Y   | V47A, V62AI  | 0   | AZT/3TC/LPV/r    | 321                | 584       |
| PAT-S17 | 49          | F   | TDF/FTC/LPV/r                    | 466                | 5146      | K65R, N69S, M184V | V47A        | 0   | TDF/3TC/LPV/r    | 292                | 685       |

NA: Not amplified; ID = participant identifier; ART = antiretroviral therapy; VL = viral load; NRTI = Nucleoside reverse transcriptase inhibitors; PI = protease inhibitors; GSS = genotypic susceptibility score

https://doi.org/10.1371/journal.pone.0236642.t002
Discussion

In this observational cohort study conducted in Côte d’Ivoire, we reported after 5 years of diagnosis of at least one drug resistance mutation to first-line ART regimen among HIV-2 patients, high mortality and lost to follow-up. Half of HIV-2 patients were not retained in care 5 years after the diagnosis of drug resistance mutation.

This high rate of mortality could be explained by the lack of access to second-line therapy for these patients in resource-limited settings. According to the US and French ART guidelines, only integrase inhibitors such as raltegravir, elvitegravir or dolutegravir or the CCR5 antagonist maraviroc (MVC) could be used as a second-line therapy among HIV-2 patients [24–28]. However, in most west African countries, these antiretroviral molecules are still scarcely available. In our study only three (9.3%) patients diagnosed with drug resistant viruses switched to the INSTI raltegravir, none of them received dolutegravir. Among the patients dead or LTFU, only one (7.1%) and two (14.2%) switched to an INSTI and to the PI darunavir, respectively. For these latter patients, the median last known CD4 count was 150 cells/mm$^3$, indicating that more than half of them were in advanced HIV disease according to the immunologic definition [29]. Increase the availability of more efficient antiretroviral drugs like integrase inhibitors is critical for patients living with HIV-2 for whom the therapeutic arsenal is limited specifically for patients harboring viruses with drug resistance mutations [15].

In resource-limited settings, there was no clear sequence of ART regimen use for the treatment of HIV-2-infected individual experiencing virologic failure [14]. This lack of clear guidelines may be the consequence of limited data on the switch of treatment among HIV-2-infected patients, the lack of routine implementation of validated tool for viral load monitoring, the absence of definition of immunological failure and the paucity of data regarding drug resistance mutations [7,8,23,30–32]. Since the mortality remains high among HIV-2 patients receiving ART [33,34], it is critical to address all the gaps and need in terms of data in order to propose clear guidelines for the treatment of HIV-2 patients experiencing virologic failure.

In the present study, six of the 17 patients remaining in care had no active antiretroviral drug in their regimen. In fact, salvage regimen for those patients with a good GSS should use boosted-darunavir and DTG which remains active in some cases of resistance to the first generation of INSTI [21,35]. Thus, in this context, genotypic resistance tests are needed in order to prevent DTG from being functional monotherapy which will result to the selection of DTG resistances. Unfortunately, according to the GSS of the patients of the present study it seems that DTG will not be sufficient and additional new drugs are needed, such as maraviroc or broad-spectrum neutralizing antibodies (Ibalizumab) [36–38]. Unfortunately, in our study population, among the 10 patients with no active ARV drug (GSS = 0), four died, arguing for the need of new therapeutic options for HIV-2 infection.

Since 2018, WHO guidelines recommend tenofovir plus lamivudine plus dolutegravir based regimen as the preferred first-line option according to expert opinion, pilot studies and in vitro data [39]. This will change the management of HIV-2-infected patients with the use of boosted-PI such as lopinavir or darunavir with an optimized NRTI-backbone in second-line [21,27,39–41]

Study limitations and strengths

Although the study was conducted in the HIV clinics with a proper documentation of patient’s follow-up, the main limitation is the lack of documentation of the cause of death. For all the
patients who were not reported dead at the HIV clinic, it was not possible to identify the clinical cause of death, as the only information available in the official death certificate was “disease”. In addition, viral load measurement was not routinely performed and only two measures (2012 and 2017) were available for the analysis, making it impossible to describe the evolution according to the switches of antiretroviral drugs during the five years of follow-up. Furthermore, this study presents data of a small population and the estimates may suffer from lack of statistic power. However, to our knowledge, this is one of the first report on treatment outcomes among HIV-2 patients who experienced virologic failure with at least one drug resistance mutation in West Africa. Data on long-term follow-up among HIV-2 patients are also limited and this study highlights the challenge to determine the sequence of ART use in this population.

**Conclusions**

Our data call for the urgent access to second-line and third-line therapy among HIV-2 patients. Clinical trials for HIV-2-infected patients harboring multi-drug resistant viruses should be conducted in both resource-limited settings and western countries. Results from the first randomized controlled trial on HIV-2 (FIT-2) Expected in 2020, will be helpful to define a sequence of ART initiation among HIV-2 patients.

**Acknowledgments**

We would like to warmly thank Drs Denise Dekpanou; Albert Minga; Eugène messou; Zelika Diallo and Serge Kooley for their contribution during the implementation of the study, as well as Mr Azany Jean Claude for his strong support in data management and study monitoring and Dr Boni Simon for his support to the clinical monitoring and critical review of the manuscript.

**Author Contributions**

**Conceptualization:** Boris K. Tchounga, Didier K. Ekouevi.

**Data curation:** Boris K. Tchounga, Charlotte Charpentier, Serge P. Eholie, Didier K. Ekouevi.

**Formal analysis:** Boris K. Tchounga, Charlotte Charpentier, Didier K. Ekouevi.

**Funding acquisition:** Boris K. Tchounga, François Dabis, Didier K. Ekouevi.

**Investigation:** Charlotte Charpentier, François Dabis, Serge P. Eholie, Didier K. Ekouevi.

**Methodology:** Boris K. Tchounga, Patrick A. Coffie, François Dabis, Diane Descamps, Serge P. Eholie, Didier K. Ekouevi.

**Project administration:** Boris K. Tchounga, Didier K. Ekouevi.

**Supervision:** Boris K. Tchounga, Diane Descamps, Serge P. Eholie, Didier K. Ekouevi.

**Validation:** Boris K. Tchounga, Charlotte Charpentier, Patrick A. Coffie, Diane Descamps, Serge P. Eholie, Didier K. Ekouevi.

**Visualization:** Patrick A. Coffie, François Dabis, Diane Descamps, Didier K. Ekouevi.

**Writing – original draft:** Boris K. Tchounga, Didier K. Ekouevi.

**Writing – review & editing:** Boris K. Tchounga, Charlotte Charpentier, Patrick A. Coffie, François Dabis, Diane Descamps, Serge P. Eholie.
References

1. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. HIV-2 molecular epidemiology. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2016 Aug 12; 

2. Faria NR, Hodges-Mamuletzis I, Silva JC, Rodés B, Erasmus S, Paolucci S, et al. Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol. 2012 Apr; 93(Pt 4):889–99. 

3. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011 Mar 15; 52(6):780–7. 

4. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14410–5. doi:10.1073/pnas.222366699 

5. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004 Feb; 9(1):57–65. PMID: 15040537 

6. Benard A, van Sighem A, Taleb A, Valadas E, Ruelle J, Soriano V, et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011 May; 52(10):1257–66. 

7. Gottlieb GS, Eholie S-P, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa: AIDS. 2008 Oct; 22(16):2069–72. doi:10.1097/QAD.0b013e32830edd44 PMID: 18832869 

8. Matheron S. HIV-2 infection: a call for controlled trials: AIDS. 2008 Oct; 22(16):2073–4. 

9. WHO. WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [Internet]. WHO. 2013 [cited 2013 Aug 10]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html 

10. Morlat P. Prise en charge médicale des personnes vivant avec le VIH Infection VIH-2; Diversité des VIH-1 [Internet]. France: Conseil national du Sida; 2016 Sep [cited 2017 Mar 27] p. 18. Report No.: septembre 2016. Available from: https://cns.sante.fr/wp-content/uploads/2017/01/experts-vih_diversite.pdf 

11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV [Internet]. USA: Department of Health and Human Services; 2017 Oct [cited 2018 Mar 27] p. 288. Report No.: 2017. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf 

12. Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 2010 Nov; 11(10):611–9. doi:10.1111/j.1468-1293.2010.00889.x PMID: 20961377 

13. WHO. Update of recommendations on first- and second-line antiretroviral regimens [Internet]. Geneva: WHO; 2019 Jul [cited 2020 Jun 20] p. 16. (HIV treatment). Report No.: WHO/CDHS-HIV/19.15. Available from: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19-15-eng.pdf?ua=1 

14. PNLCS Côte d’Ivoire. Directives nationales 2015 de Prise En Charge des Personnes Vivant avec le VIH [Internet]. Programme National de Lutte contre le Sida (PNLCS); 2015 [cited 2018 Mar 28]. Available from: http://www.pnls-ci.com/documentation/directives-2015-de-pcc-des-personnes-vivant-avec-le-vih/ 

15. Charpentier C, Eholié S, Anglaret X, Berline M, Rouzioux C, Avertand-Fenoll V, et al. Genotypic resistance profiles of HIV-2-treated patients in West Africa. AIDS Lond Engl. 2014 May 15; 28(8):1161–9. 

16. Gottlieb GS, Badiane NMD, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009 Feb 15; 49(4):476–83. 

17. Raugi DN, Smith RA, Ba S, Toure M, Traore F, Sall F, et al. Complex patterns of protease inhibitor resistance among antiretroviral-treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother. 2013 Jun; 57(6):2571–60. doi:10.1128/AAC.00405-13 PMID: 23571535 

18. Jallow S, Aliabi A, Sarge-Njie R, Petersen K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol. 2009 Jul; 47(7):2200–8. doi:10.1128/JCM.01654-08 PMID: 19420165
19. Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, et al. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. Antivir Ther. 2004 Aug; 9(4):635–6. PMID: 15456096

20. Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS Lond Engl. 2008 Oct 1; 22(15):2045–6.

21. Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, et al. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015 May 15; 60(10):1521–7.

22. Ekouevi DK, Balestre E, Coffie PA, Minta D, Messou E, Sawadogo A, et al. Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study. PloS One. 2013; 8(6):e66135. https://doi.org/10.1371/journal.pone.0066135 PMID: 23824279

23. Avettand-Fenoël V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, et al. A new sensitive one-step real-time duplex PCR method for groups A and B HIV-2 RNA load. J Clin Microbiol. 2014 Jun 11; JCM.00724–14.

24. Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors. Antimicrob Agents Chemother. 2012 Jan; 56(1):137–9. https://doi.org/10.1128/AAC.05313-11 PMID: 22064539

25. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bernard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008 Nov; 62(5):914–20. https://doi.org/10.1093/jac/dkn335 PMID: 18718922

26. Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS Lond Engl. 2010 Nov 13; 24(17):2753–5.

27. Smith RA, Raugi DN, Pan C, Sow PS, Seydi M, Mullins J, et al. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology. 2015 Feb 5; 12:10. https://doi.org/10.1186/s12977-015-0146-8 PMID: 25908007

28. Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, et al. Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens. PLOS ONE. 2012 Sep 18; 7(9):e45372. https://doi.org/10.1371/journal.pone.0045372 PMID: 23028968

29. Waldrop G, Doherty M, Vitoria M, Ford N. Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy. Trop Med Int Health TM IH. 2016; 21(9):1124–30. https://doi.org/10.1111/tmi.12746 PMID: 27371814

30. Chang M, Gottlieb GS, Dragavon JA, Chene SL, Kenney DL, Hawes SE, et al. Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2012 Oct; 55(2):128–33.

31. Styer LM, Miller TT, Parker MM. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2013 Dec;58 Suppl 1: e127–133.

32. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Res Treat. 2011; 2011:463704. https://doi.org/10.1155/2011/463704 PMID: 21490779

33. Tchounga B, Ekouevi DK, Balestre E, Dabis F. Mortality and survival patterns of people living with HIV-2. Curr Opin HIV AIDS. 2016 May 31;

34. Tchounga BK, Henge BL, Eholie SP, Coffie PA, Jespersen S, Wejse C, et al. Effect of sex and age on outcomes among HIV-2 infected patients starting antiretroviral therapy in west africa: a multicentre cohort study. AIDS Lond Engl. 2016 Aug 17;

35. Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet J-F, et al. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther. 2011; 16(6):937–40. https://doi.org/10.3851/IMP1826 PMID: 21900727

36. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol. 2012 Jan; 86(2):497–60. https://doi.org/10.1128/JVI.00155-11 PMID: 22031948

37. Borrego P, Taveira N. HIV-2 susceptibility to entry inhibitors. AIDS Rev. 2013 Mar; 15(1):49–61. PMID: 23449229
38. Caixas U, Ferreira J, Marinho AT, Faustino I, Grilo NM, Lampreia F, et al. Long-term maraviroc use as salvage therapy in HIV-2 infection. J Antimicrob Chemother. 2012 Oct; 67(10):2538–9. https://doi.org/10.1093/jac/dks240 PMID: 22729923

39. Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, et al. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 28; 67 (8):1161–7.

40. Ba S, Raugi DN, Smith RA, Sall F, Faye K, Hawes SE, et al. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 30; 67(10):1588–94.

41. World Health Organization. UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV [Internet]. World Health Organization; 2018 Dec [cited 2019 Nov 1] p. 82. (Antiretroviral Treatment). Report No.: 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/277395/WHO-CDS-HIV-18.51-eng.pdf?ua=1